Key result
Tricuspid valve replacement shows no 10-year survival benefit over repair in rheumatic tricuspid regurgitation reoperations.
Why the study?
Reoperation for isolated tricuspid regurgitation in rheumatic patients is rare and its outcomes remain unclear and controversial due to limited publications.
Cohort (n=26)
No
Reoperation for isolated rheumatic tricuspid regurgitation carries a 15.4% operative mortality but provides acceptable long-term survival, emphasizing the need for intervention before the onset of right ventricular dysfunction.
Isolated TV reoperation feasible in rheumatic patients; leaves open optimal timing and technique in this rare setting.
BACKGROUND: The reoperation for isolated tricuspid regurgitation in rheumatic population is rare and still unclear and controversial because of the rarity of publications. The aim of this study was to analyze short and long-term results and outcome of tricuspid valve surgery after left-sided valve surgery in rheumatic patients. METHODS: Twenty six consecutive rheumatic patients who underwent isolated tricuspid valve surgery after left-sided valve surgery between January 2000 and January2017 were retrospectively registered in the study. The mean age was 48.2 ± 8.6 years with 8.3% as sex-ratio (M/F). EuroSCORE was 6.1 ± 5 (range 2.5 to 24.1). The mechanism of tricuspid regurgitation was functional and organic in respectively 14 (53.8%) and 12 cases (46.2%). Ten patients (38.5%) had previous tricuspid valve repair. Surgery consisted of 15 ring annuloplasty and 11 tricuspid valve replacement (5 bioprostheses and 6 mechanical prostheses). Follow-up was 96.1% complete, with a mean follow-up of 55.6 ± 38.8 months (range 1 to 165). RESULTS: The operative mortality rate was 15.4% (n = 4) and the cumulative survival at 1, 5 and 10 years was respectively 80% ± 8%, 75.6% ± 8.7% and 67.2% ± 11.1% with no significant difference at 8 years between tricuspid valve replacement (80% ± 12.6%) and repair (57.6% ± 16.1%) (p = 0.5). Multivariable Cox regression analysis revealed that ascites (HR, 5.8; p = 0.01), and right ventricular dysfunction (HR, 0.94; p = 0.001) were predictors of major adverse cardiac events. There were no recurrence of tricuspid regurgitation and no structural or non-structural deterioration of valvular prostheses. CONCLUSION: The reoperation of rheumatic tricuspid regurgitation should be considered before the installation of complications such as right ventricular dysfunction and major signs of right heart failure. Despite the superiority of repair techniques, tricuspid valve replacement should not be banished.
No takes yet. Share an insight, caveat, or question.
Moutakiallah et al. (2018) conducted a cohort in Isolated rheumatic tricuspid regurgitation (n=26). Tricuspid valve replacement vs. Tricuspid valve repair was evaluated on 10-year cumulative survival (p=0.52). Tricuspid valve replacement showed no significant difference in 10-year cumulative survival compared to tricuspid valve repair (80% vs 60%, p=0.52) in patients undergoing reoperation for isolated rheumatic tricuspid regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: